Study:
Phase II Randomized Evaluation of 5-Lipoxygenase Inhibition by Herbal Complementary and Alternative Medicine Approach Compared to Control as an Adjuvant Therapy in Newly Diagnosed and Recurrent High-grade Gliomas
Rationale:
Giving the herb Boswellia serrata after surgery and radiation therapy may slow
the growth of any remaining tumor cells. It is not yet known whether giving Boswellia
serrata together with standard treatment is more effective than standard treatment alone in
treating high-grade gliomas.
Purpose:
This randomized phase II trial is the study of a combination of complementary and
alternative medicine (CAM) herbal supplement intervention as an adjuvant to standard
treatment of patients with newly diagnosed and recurrent high-grade gliomas (HGG). The
central hypothesis of this application is that a herbal preparation that inhibits 5-LO
activity, will produce measurable biologically meaningful decrease in 5-LO eicosanoid
production and brain edema that will be associated with improved survival and quality of
like in patients with HGG.
Study Status: Active, not recruiting
Recruiting:
n/a
| Condition |
Intervention |
Phase |
Brain and Central Nervous System Tumors
Cerebral Edema |
Dietary Supplement: Boswellia serrata extract
Dietary Supplement: cyanocobalamin |
Phase 2 |
Verified by
Case Comprehensive Cancer Center
September, 2012
Sponsored by: Case Comprehensive Cancer Center
Information provided by: Case Comprehensive Cancer Center
ClinicalTrials.gov identifier: NCT00243022
Study Type: Interventional
Study Design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
Cleveland, Ohio 44195
United States
Glen Stevens, DO, PhD., Principal Investigator